Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia

Carla Mamolo*, Verna Welch, Roland B Walter, Joseph C Cappelleri, James Brockbank, Matthew Cawson, Chris Knight, Michele Wilson

*Carla Mamolo, Patient & Health Impact, Pfizer Inc, Groton, CT, USA; Email: carla.mamolo@pfizer.com

Online Resource 3. Drug dose and cost for R/R AML.

Treatment	Mean dose	Doses per course	Cost per course (US$)[a]
GO[b]			
Adults	3 mg/m^2	1.8	15,829.43
Pediatric patients	3 mg/m^2	3.0	27,010.80
HiDAC			
HiDAC 1000–1500 mg/m^2, IV	2000 mg/m^2	1	53.84
Daunorubicin 45–60 mg/m^2, IV	45 mg/mg^2	3	1,297.01
Idarubicin 8–10 mg/m^2, IV	8 mg/m^2	3	1,077.71
Mitoxantrone 8–10 mg/m^2, IV	8 mg/m^2	3	830.88
HiDAC total cost	–	–	3,248.31
FLAG-IDA			
Fludarabine 30 mg/m^2, IV	30 mg/m^2	3	939.86
Cytarabine 1500–2000 mg/m^2	1500 mg/m^2	3	129.53
Idarubicin 10 mg/m^2, IV	10 mg/m^2	3	1,284.52
G-CSF 5 mg/kg, SC	263 mg/kg	7	6,685.81
FLAG-IDA total cost	–	–	9,039.71
MEC			
Mitoxantrone 8 mg/m^2	8 mg/m^2	3	830.88
Etoposide 100 mg/m^2	100 mg/m^2	3	68.27
Cytarabine 1000 mg/m^2	1000 mg/m^2	3	128.14
MEC total cost	–	–	1,027.29

[a] Drug unit prices obtained from Red Book [1].

[b] The mean number of doses received per course of treatment is calculated using a weighted calculation based on the data reported in Larson et al [2] due to lack of available data in Taksin et al [3] for the number of doses received in the first course of treatment.

AML acute myeloid leukemia; *FLAG-IDA* fludarabine, cytarabine, G-CSF, and idarubicin; *G-CSF* granulocyte colony-stimulating factor; *GO* gemtuzumab ozogamicin; *HiDAC* high-dose cytarabine, mitoxantrone, daunorubicin, and idarubicin; *IV* intravenous; *MEC* mitoxantrone, etoposide, and cytarabine; *R/R* relapsed/refractory; *SC* subcutaneous.

References:

1. Truven Health. Red Book® Online. 2017. Available at: https://www.ibm.com/us-en/marketplace/micromedex-red-book [Accessed April 10, 2020].
2. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-52.
3. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 2007;21:66-71.